Alexion Pharmaceuticals announces acquisition of Portola Pharmaceuticals

Alexion Pharmaceuticals to acquire Portola Pharmaceuticals, which is another blood disease-focused biotech company, for $18 per share.



”The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care. By leveraging Alexion’s strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."
Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion
The_MergerSight_Group_Instagram
The_MergerSight_Group_LinkedIn
The_MergerSight_Group_Facebook

© 2018 - 2020 The MergerSight Group

Subscribe to Newsletter